healthcareЗдравоохранение. HealthcareHealthcare1027-7218Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Health Economicshealthcare-141Research ArticleСЛУЧАИ ИЗ ПРАКТИКИCASES FROM PRACTICEМиксоидная нейрофибромаMyxoid neurofibromaСопичИ. В.SopichI. V.

Минск

ГарбульА. А.HarbulA. A.

Минск

БарановскаяЮ. Ю.BaranouskayaYu. Yu.

Минск

ЕрошенкоА. В.EroshenkoA. V.

Минск

КишкоС. Н.KiyashkoS. N.

Минск

ООО «Клиника «Мерси»BelarusМинский клинический консультативно-диагностический центрBelarusООО «Здоровое решение»BelarusМинский городской клинический онкологический центрBelarus2024230920251845—51Copyright © Сопич И.В., Гарбуль А.А., Барановская Ю.Ю., Ерошенко А.В., Кишко С.Н., 20252025Сопич И.В., Гарбуль А.А., Барановская Ю.Ю., Ерошенко А.В., Кишко С.Н.Sopich I.V., Harbul A.A., Baranouskaya Y.Y., Eroshenko A.V., Kiyashko S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://healthcare.ejournal.by/jour/article/view/141

Цель исследования. Выявить объемное образование мягких тканей в правой подмышечной области у пациентки с отягощенным наследственным анамнезом (рак молочной железы у матери).Материал и методы. Представлено собственное наблюдение редкой патологии, выявленной с помощью инструментальных методов исследования. Приводятся современные данные литературы о распространенности, особенностях клинического и гистоморфологического проявлений миксоидной нейрофибромы.Результаты. Инструментальные методы исследования установили точную локализацию опухоли, ее топографическое расположение по отношению к окружающим тканям, что позволило в полном объеме выполнить хирургическое удаление опухоли. Однако заключительный диагноз «миксоидная нейрофиброма» поставлен на основании результатов гистологического исследования.Заключение. Дифференциальная диагностика миксоидной нейрофибромы с помощью инструментальных методов исследования имеет ограничения. Точная постановка диагноза основывается на данных гистологической верификации опухоли и молекулярно-генетического тестирования. 

Objective

Objective. Detection of voluminous formation of soft tissues in the right axillary region in a patient with an aggravated hereditary anamnesis (having a mother diagnosed with breast cancer).

Materials and methods

Materials and methods. The authors present their own observation of a rare pathology detected with the help of instrumental methods of research. The current literature data on the prevalence, peculiarities of clinical and histomorphological manifestations of myxoid neurofibroma are presented.

Results

Results. Instrumental research methods have established the exact localization of the tumor, its topographic location in relation to the surrounding tissues, which made it possible to perform surgical removal of the lump in full. However, the final diagnosis: myxoid neurofibroma is based on the results of histological examination.

Conclusion

Conclusion. Differential diagnosis of myxoid neurofibroma using instrumental research methods has limitations. The exact diagnosis is based on the data of histological verification of the tumor and molecular genetic testing.

нейрофиброматозмиксоидная нейрофибромамолекулярно-генетическое тестированиеиммунофенотип S100+ЕМА+хирургическое лечениеneurofibromatosismyxoid neurofibromamolecular genetic testingS100+ immunophenotypeEMA+surgical treatmentReferencesUhlmann, E. J. Neurofibromatoses / E. J. Uhlmann, S. R. Plotkin // Adv. Exp. Med. Biol. — 2012. — № 724. — P. 266—277.Uhlmann, E. J. Neurofibromatoses / E. J. Uhlmann, S. R. Plotkin // Adv. Exp. Med. Biol. — 2012. — № 724. — P. 266—277.Becker, B. Phakomatoses / B. Becker, R. E. Strowd // Dermatologic Clin. — 2019. — № 37. — P. 583—606.Becker, B. Phakomatoses / B. Becker, R. E. Strowd // Dermatologic Clin. — 2019. — № 37. — P. 583—606.Ostendorf, A. P. Neurofibromatoses / A. P. Ostendorf, D. H. Gutmann // Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease / eds.: R. N. Rosenberg, J. M. Pascual. — Massachusett, 2015. — P. 921—933.Ostendorf, A. P. Neurofibromatoses / A. P. Ostendorf, D. H. Gutmann // Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease / eds.: R. N. Rosenberg, J. M. Pascual. — Massachusett, 2015. — P. 921—933.D’Gama, A. M. Somatic mosaicism and neurodevelopmental disease / A. M. D’Gama, C. A. Walsh // Nature Neurosci. — 2018. — № 21. — P. 1504—1514.D’Gama, A. M. Somatic mosaicism and neurodevelopmental disease / A. M. D’Gama, C. A. Walsh // Nature Neurosci. — 2018. — № 21. — P. 1504—1514.Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing / D. G. Evans [et al.] // Genet. Med. — 2020. — Vol. 22, № 1. — P. 53—59.Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing / D. G. Evans [et al.] // Genet. Med. — 2020. — Vol. 22, № 1. — P. 53—59.Clinical features of 58 Japanese patients with mosaic neurofibromatosis 1 / K. Tanito [et al.] // J. Dermatology. — 2014. — Vol. 41, № 8. — P. 724—728.Clinical features of 58 Japanese patients with mosaic neurofibromatosis 1 / K. Tanito [et al.] // J. Dermatology. — 2014. — Vol. 41, № 8. — P. 724—728.Identifying challenges in neurofibromatosis: a modified Delphi procedure / B. A. Dhaenens [et al.] // Eur. J. Hum. Genet. — 2021. — Vol. 29, № 11. — P. 1—9.Identifying challenges in neurofibromatosis: a modified Delphi procedure / B. A. Dhaenens [et al.] // Eur. J. Hum. Genet. — 2021. — Vol. 29, № 11. — P. 1—9.Neurofibromatosis type 1: review and update on emerging therapies / T. Karaconji [et al.] // Asia Pac. J. Ophthalmol. — 2019. — Vol. 8, № 1. — P. 62—72.Neurofibromatosis type 1: review and update on emerging therapies / T. Karaconji [et al.] // Asia Pac. J. Ophthalmol. — 2019. — Vol. 8, № 1. — P. 62—72.Early genetic diagnosis of neurofibromatosis type 2 from skin plaque plexiform schwannomas in childhood / E. Castellanos [et al.] // JAMA Dermatol. — 2018. — Vol. 154, № 3. — P. 341—346.Early genetic diagnosis of neurofibromatosis type 2 from skin plaque plexiform schwannomas in childhood / E. Castellanos [et al.] // JAMA Dermatol. — 2018. — Vol. 154, № 3. — P. 341—346.Neurofibromatosis type 1 / D. H. Gutmann [et al.] // Nat. Rev. Dis. Primers. — 2017. — Vol. 23, № 3. — P. 1—7.Neurofibromatosis type 1 / D. H. Gutmann [et al.] // Nat. Rev. Dis. Primers. — 2017. — Vol. 23, № 3. — P. 1—7.Hernandez-Martin, A. An update on neurofibromatosis type 1: not just Cafe-au-Lait spots and freckling. Part II. Other skin manifestations characteristic of NF1. NF1 and cancer / A. Hernandez-Martin, A. Duat-Rodriguez // Actas Dermo-Sifiliograficas (Eng. Edn). — 2016. — Vol. 107, iss. 6. — P. 465—473.Hernandez-Martin, A. An update on neurofibromatosis type 1: not just Cafe-au-Lait spots and freckling. Part II. Other skin manifestations characteristic of NF1. NF1 and cancer / A. Hernandez-Martin, A. Duat-Rodriguez // Actas Dermo-Sifiliograficas (Eng. Edn). — 2016. — Vol. 107, iss. 6. — P. 465—473.Severe thoracic and spinal bone abnormalities in neurofibromatosis type 1 / L. Prudhomme [et al.] // Eur. J. Med. Genet. — 2020. — Vol. 63, № 4. — P. 103815.Severe thoracic and spinal bone abnormalities in neurofibromatosis type 1 / L. Prudhomme [et al.] // Eur. J. Med. Genet. — 2020. — Vol. 63, № 4. — P. 103815.Craniofacial bone alterations in patients with neurofibromatosis type 1 / J. Chauvel-Picard [et al.] // Childs. Nerv. Syst. — 2020. — Vol. 36, № 10. — P. 2391—2399.Craniofacial bone alterations in patients with neurofibromatosis type 1 / J. Chauvel-Picard [et al.] // Childs. Nerv. Syst. — 2020. — Vol. 36, № 10. — P. 2391—2399.Messersmith, L. Neurofibroma [Electronic resource] / L. Messersmith, K. Krauland — StatPearls Publishing, 2021. — Mode of access: https://www.statpearls.com/pointof-care/25784. — Date of access: 24.04.2024.Messersmith, L. Neurofibroma [Electronic resource] / L. Messersmith, K. Krauland — StatPearls Publishing, 2021. — Mode of access: https://www.statpearls.com/pointof-care/25784. — Date of access: 24.04.2024.Garozzo, D. Peripheral nerve tumors in neurofibromatosis 1 : an overview on management and indications for surgical treatment in our experience / D. Garozzo // Neurol. India. — 2019. — Vol. 67 (Suppl.). — P. 38—S44.Garozzo, D. Peripheral nerve tumors in neurofibromatosis 1 : an overview on management and indications for surgical treatment in our experience / D. Garozzo // Neurol. India. — 2019. — Vol. 67 (Suppl.). — P. 38—S44.Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1 / A. M. Gross [et al.] // Neurol. Oncol. — 2018. — Vol. 20, № 12. — P. 1643—1651.Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1 / A. M. Gross [et al.] // Neurol. Oncol. — 2018. — Vol. 20, № 12. — P. 1643—1651.Nix, J. S. An update on the central nervous system manifestations of neurofibromatosis type 1 / J. S. Nix, J. Blakeley, F. J. Rodriguez // Acta Neuropathol. — 2020. — Vol. 139, № 4. — P. 625—641.Nix, J. S. An update on the central nervous system manifestations of neurofibromatosis type 1 / J. S. Nix, J. Blakeley, F. J. Rodriguez // Acta Neuropathol. — 2020. — Vol. 139, № 4. — P. 625—641.Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience / C. Santoro [et al.] // Am. J. Med. Genet. A. — 2017. — Vol. 173, № 6. — P. 1521—1530.Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience / C. Santoro [et al.] // Am. J. Med. Genet. A. — 2017. — Vol. 173, № 6. — P. 1521—1530.Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1 / H. Morotti [et al.] // Dev. Med. Child. Neurol. — 2021. — Vol. 63, № 2. — P. 226—232.Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1 / H. Morotti [et al.] // Dev. Med. Child. Neurol. — 2021. — Vol. 63, № 2. — P. 226—232.Neurofibromatosis type 1 and cardiac manifestations / F. Incecik [et al.] // Turk. Kardiyol. Dern. Ars. — 2015. — Vol. 43, № 8. — P. 714—716.Neurofibromatosis type 1 and cardiac manifestations / F. Incecik [et al.] // Turk. Kardiyol. Dern. Ars. — 2015. — Vol. 43, № 8. — P. 714—716.Epilepsy in neurofibromatosis type 1 / A. Pecoraro [et al.] // Epilepsy Behav. — 2017. — Vol. 73. — P. 137—141.Epilepsy in neurofibromatosis type 1 / A. Pecoraro [et al.] // Epilepsy Behav. — 2017. — Vol. 73. — P. 137—141.Yapijakis, C. Neurofibromatosis-Noonan syndrome: a possible paradigm of the combination of genetic and epigenetic factors // C. Yapijakis, N. Pachis, C. Voumvourakis // Adv. Exp. Med. Biol. — 2017. — Vol. 987. — P. 151—159.Yapijakis, C. Neurofibromatosis-Noonan syndrome: a possible paradigm of the combination of genetic and epigenetic factors // C. Yapijakis, N. Pachis, C. Voumvourakis // Adv. Exp. Med. Biol. — 2017. — Vol. 987. — P. 151—159.Kehrer-Sawatzki, H. Classification of NF1 microdeletions and its importance for establishing genotype/ phenotype correlations in patients with NF1 microdeletions / H. Kehrer-Sawatzki, D. N. Cooper // Hum. Genet. — 2021. — Vol. 140, № 12. — P. 1635—1649.Kehrer-Sawatzki, H. Classification of NF1 microdeletions and its importance for establishing genotype/ phenotype correlations in patients with NF1 microdeletions / H. Kehrer-Sawatzki, D. N. Cooper // Hum. Genet. — 2021. — Vol. 140, № 12. — P. 1635—1649.Tadini, G. Mosaic NF1 / G. Tadini, T. Schgor, M. Brena // Multidisciplinary Approach to Neurofibromatosis Type 1 / eds.: G. Tadini, E. Legius, H. Brems. — New York, 2020.Tadini, G. Mosaic NF1 / G. Tadini, T. Schgor, M. Brena // Multidisciplinary Approach to Neurofibromatosis Type 1 / eds.: G. Tadini, E. Legius, H. Brems. — New York, 2020.Genotype-phenotype correlations in neurofibromatosis type 1: a singlecenter cohort study / M. Scala [et al.] // Cancers (Basel). — 2021. — Vol. 13, № 8. — P. 1879.Genotype-phenotype correlations in neurofibromatosis type 1: a singlecenter cohort study / M. Scala [et al.] // Cancers (Basel). — 2021. — Vol. 13, № 8. — P. 1879.Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844—848 / M. Koczkowska [et al.] // Am. J. Hum. Genet. — 2018. — Vol. 102, № 1. — P. 69—87.Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844—848 / M. Koczkowska [et al.] // Am. J. Hum. Genet. — 2018. — Vol. 102, № 1. — P. 69—87.p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas / V. Pinna [et al.] // Eur. J. Hum. Genet. —2015. — Vol. 23, № 8. — P. 1068—1071.p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas / V. Pinna [et al.] // Eur. J. Hum. Genet. —2015. — Vol. 23, № 8. — P. 1068—1071.Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1 / O. Maertens [et al.] // Am. J. Hum. Genet. — 2007. — Vol. 81, № 2. — P. 243—251.Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1 / O. Maertens [et al.] // Am. J. Hum. Genet. — 2007. — Vol. 81, № 2. — P. 243—251.

The authors declare that there are no conflicts of interest present.